Hongfei Zhu

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Combination Therapy

Top Venues

Journal of oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Kang Wang, Hongfei Zhu, Hongming Yu, Yuqiang Cheng, Yan-Jun Xiang, Zhangjun Cheng, Yang Li, Tao Li, Dongxu Wang, Zhenyu Zhu, Shu-Qun Cheng
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. Journal of oncology 2023 (2023)
Kang Wang, Hongfei Zhu, Hongming Yu, Yuqiang Cheng, Yan-Jun Xiang, Zhangjun Cheng, Yang Li, Tao Li, Dongxu Wang, Zhenyu Zhu, Shu-Qun Cheng
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. Journal of oncology 2023 (2023)
Kang Wang, Hongfei Zhu, Hongming Yu, Yuqiang Cheng, Yan-Jun Xiang, Zhangjun Cheng, Yang Li, Tao Li, Dongxu Wang, Zhenyu Zhu, Shu-Qun Cheng
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. Journal of oncology 2023 (2023)
Kang Wang, Hongfei Zhu, Hongming Yu, Yuqiang Cheng, Yan-Jun Xiang, Zhangjun Cheng, Yang Li, Tao Li, Dongxu Wang, Zhenyu Zhu, Shu-Qun Cheng
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. Journal of oncology 2023 (2023)